Equity Profile

RPRX

Royalty Pharma plc

Health CarePharmaceuticals$24.8B

Aug5Wed

Pre-Earnings Brief

UpcomingQ4-2017Pre-Market9:00 AM EDT

Company Snapshot

Royalty Pharma plc (RPRX) is a healthcare company that focuses on acquiring and managing revenue-generating pharmaceutical royalties. With a market cap of $24 billion, it plays a crucial role in the pharmaceutical industry by providing funding to drug developers while sharing in their future profits.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability, and this quarter, analysts expect RPRX to report $1.18, reflecting its ability to generate earnings.

$1.18

Revenue

Revenue growth is essential for assessing the company's financial health and operational performance, with expectations set at $874 million.

$874M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RPRX Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

+5.28%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter, Royalty Pharma reported a loss of $0.04 per share, which was below expectations. The company did not provide specific guidance, leaving investors uncertain about future performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about RPRX's upcoming earnings, with expectations of a modest profit and steady revenue. The consensus EPS is $1.18, indicating a potential recovery in earnings.

Bull Case

If RPRX meets or exceeds the EPS and revenue expectations, it could signal a strong turnaround in profitability, boosting investor confidence and stock price.

Bear Case

Conversely, if the company fails to meet these expectations, it may reinforce concerns about its profitability and growth trajectory, leading to a negative market reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.18

EPS is a key indicator of profitability, and this quarter, analysts expect RPRX to report $1.18, reflecting its ability to generate earnings.

Revenue

$874M

Revenue growth is essential for assessing the company's financial health and operational performance, with expectations set at $874 million.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will RPRX achieve an EPS of at least $1.18?

This figure is crucial as it reflects the company's ability to generate profits and will heavily influence investor sentiment.

How does RPRX's revenue compare to the $874 million consensus?

Revenue performance is a key indicator of the company's operational success and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating RPRX's potential for a strong earnings rebound, given its recent focus on acquiring lucrative royalties.

Supporting Evidence

The company has a history of surprising on the upside, and current market conditions may favor its revenue model.

Options pricing indicates significant volatility, suggesting that investors are bracing for a potential positive surprise.

Key Risk

If RPRX's revenue exceeds $874 million, it could shift the market's perception significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will determine whether RPRX can stabilize its earnings and regain investor confidence.

Bull Confirmed If

Achieving an EPS of $1.18 or higher would confirm the bull case and suggest a strong recovery in profitability.

Bear Confirmed If

An EPS below $1.17 would validate the bear case, indicating ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±12.9%

The options market is pricing in a significant move of nearly 13% in either direction following the earnings report, indicating heightened uncertainty among investors.

Detail

ATM IV

0.3%

30d HV

19.2%

Calls (25K)P/C Ratio: 0.01Puts (0)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

84.49%

of float

Insider

7.12%

of float

Holders

844

institutions

Top Holders· as of Dec 2025

Morgan Stanley
55,274,069 sh · $2.7B
12.44%
25.2%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If RPRX beats expectations, history suggests the stock could rise by an average of 3.0% on the day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline, with historical data suggesting an average drop of around 2.05% in such scenarios.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new royalty agreements or acquisitions that could enhance revenue.
2Management's commentary on the overall market environment and its impact on future earnings.
3Details on cost management strategies that could improve profit margins.
4Insights into the pipeline of drugs that may contribute to future royalties.
5Any guidance or outlook for the next quarter that could indicate growth potential.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability, and this quarter, analysts expect RPRX to report $1.18, reflecting its ability to generate earnings.

$1.18

Revenue

Revenue growth is essential for assessing the company's financial health and operational performance, with expectations set at $874 million.

$874M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RPRX Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

+5.28%

Avg Stock Reaction

+0.00%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about RPRX's upcoming earnings, with expectations of a modest profit and steady revenue. The consensus EPS is $1.18, indicating a potential recovery in earnings.

Bull Case

If RPRX meets or exceeds the EPS and revenue expectations, it could signal a strong turnaround in profitability, boosting investor confidence and stock price.

Bear Case

Conversely, if the company fails to meet these expectations, it may reinforce concerns about its profitability and growth trajectory, leading to a negative market reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.18

EPS is a key indicator of profitability, and this quarter, analysts expect RPRX to report $1.18, reflecting its ability to generate earnings.

Revenue

$874M

Revenue growth is essential for assessing the company's financial health and operational performance, with expectations set at $874 million.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will RPRX achieve an EPS of at least $1.18?

This figure is crucial as it reflects the company's ability to generate profits and will heavily influence investor sentiment.

How does RPRX's revenue compare to the $874 million consensus?

Revenue performance is a key indicator of the company's operational success and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating RPRX's potential for a strong earnings rebound, given its recent focus on acquiring lucrative royalties.

Supporting Evidence

The company has a history of surprising on the upside, and current market conditions may favor its revenue model.

Options pricing indicates significant volatility, suggesting that investors are bracing for a potential positive surprise.

Key Risk

If RPRX's revenue exceeds $874 million, it could shift the market's perception significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will determine whether RPRX can stabilize its earnings and regain investor confidence.

Bull Confirmed If

Achieving an EPS of $1.18 or higher would confirm the bull case and suggest a strong recovery in profitability.

Bear Confirmed If

An EPS below $1.17 would validate the bear case, indicating ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±12.9%

The options market is pricing in a significant move of nearly 13% in either direction following the earnings report, indicating heightened uncertainty among investors.

Detail

ATM IV

0.3%

30d HV

19.2%

Calls (25K)P/C Ratio: 0.01Puts (0)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

84.49%

of float

Insider

7.12%

of float

Holders

844

institutions

Top Holders· as of Dec 2025

Morgan Stanley
55,274,069 sh · $2.7B
12.44%
25.2%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If RPRX beats expectations, history suggests the stock could rise by an average of 3.0% on the day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline, with historical data suggesting an average drop of around 2.05% in such scenarios.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new royalty agreements or acquisitions that could enhance revenue.
2Management's commentary on the overall market environment and its impact on future earnings.
3Details on cost management strategies that could improve profit margins.
4Insights into the pipeline of drugs that may contribute to future royalties.
5Any guidance or outlook for the next quarter that could indicate growth potential.